Key Documents

View All Documentation

444375

N-Benzoyl-(2R,3S)-3-phenylisoserine

Name: N-Benzoyl-(2R,3S)-3-phenylisoserine
Brand: ALDRICH

98%

Select a Size

Change View

About This Item

Linear Formula:

C₆H₅CONHCH(C₆H₅)CH(OH)CO₂H

CAS Number:

132201-33-3

Molecular Weight:

285.29

UNSPSC Code:

12352209

eCl@ss:

32160406

PubChem Substance ID:

24868119

NACRES:

NA.22

MDL number:

MFCD00274633

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Quality Level

100

assay

98%

optical activity

[α]20/D −40°, c = 1.0 in ethanol

reaction suitability

reaction type: solution phase peptide synthesis

mp

169-172 °C (lit.)

application(s)

peptide synthesis

SMILES string

O[C@H]([C@@H](NC(=O)c1ccccc1)c2ccccc2)C(O)=O

InChI

1S/C16H15NO4/c18-14(16(20)21)13(11-7-3-1-4-8-11)17-15(19)12-9-5-2-6-10-12/h1-10,13-14,18H,(H,17,19)(H,20,21)/t13-,14+/m0/s1

InChI key

HYJVYOWKYPNSTK-UONOGXRCSA-N

Description

Application

The presence of this chiral side chain has proven to be essential for the biological activity of taxol, one of the most promising anticancer agents being investigated. The challenging synthesis of taxol has stimulated interest in the attachment of the C-13 side chain to naturally derived taxanes like baccatin III.

pictograms

GHS07

signalword

Warning

hcodes

H315,H319,H335

pcodes

P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sequences of taxol and cisplatin: a phase I and pharmacologic study.

E K Rowinsky et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 9(9), 1692-1703 (1991-09-01)

Untreated and minimally pretreated solid tumor patients received alternating sequences of taxol and cisplatin. Sequential dose escalation of each agent using taxol doses of 110 or 135 mg/m2 and cisplatin doses of 50 or 75 mg/m2 resulted in four dosage

Ojima, I. et al.

Tetrahedron Letters, 34, 4149-4149 (1993)

Mangatal, L. et al.

Tetrahedron, 45, 4177-4177 (1989)

View All Related Papers

Global Trade Item Number

SKU	GTIN
444375-500MG	04061832594613